Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 175 of 178 entries
View as:

Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00193531 Org: User:
Start: 12/31/98 End: 01/31/07 Due: 01/31/08

Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00193258 Org: User:
Start: 06/30/04 End: 08/31/11 Due: 08/31/12

Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00294931 Org: User:
Start: 02/28/06 End: 01/31/09 Due: 01/31/10

Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting

Phase: N/A Priority: Normal
NCT ID: NCT00877045 Org: User:
Start: 01/31/08 End: 02/28/09 Due: 02/28/10

Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00193011 Org: User:
Start: 03/31/02 End: 08/31/04 Due: 08/31/05

A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)

Phase: N/A Priority: Normal
NCT ID: NCT01490866 Org: User:
Start: 01/31/12 End: 07/31/15 Due: 07/31/16

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05748834 Org: User:
Start: 07/24/23 End: 07/31/26 Due: 07/31/27

Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01496118 Org: User:
Start: 12/31/11 End: 12/31/20 Due: 12/31/21

Vinflunine in Hormone Refractory Prostate Cancer (HRPC)

Phase: N/A Priority: Normal
NCT ID: NCT00545766 Org: User:
Start: 05/31/07 End: 01/31/09 Due: 01/31/10

Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site

Phase: N/A Priority: Normal
NCT ID: NCT00737243 Org: User:
Start: 08/31/08 End: 12/31/12 Due: 12/31/13

Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00294190 Org: User:
Start: 02/28/06 End: 07/31/09 Due: 07/31/10

Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT00621049 Org: User:
Start: 12/31/07 End: 02/28/14 Due: 02/28/15

Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00193427 Org: User:
Start: 04/30/04 End: 12/31/08 Due: 12/31/09

Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide

Phase: N/A Priority: Normal
NCT ID: NCT04361058 Org: User:
Start: 04/13/20 End: 04/20/21 Due: 04/20/22

Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00193466 Org: User:
Start: 01/31/02 End: 04/30/08 Due: 04/30/09

Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00193206 Org: User:
Start: 09/30/05 End: 05/31/09 Due: 05/31/10

Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma

Phase: N/A Priority: Normal
NCT ID: NCT00972335 Org: User:
Start: 01/31/10 End: 07/31/14 Due: 07/31/15

Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00193414 Org: User:
Start: 05/31/05 End: 08/31/09 Due: 08/31/10

Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00544167 Org: User:
Start: 05/31/07 End: 04/30/11 Due: 04/30/12

Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

Phase: N/A Priority: Normal
NCT ID: NCT03977467 Org: User:
Start: 08/30/19 End: 08/09/24 Due: 08/09/25

Treatment of Head & Neck Cancer With Chemotherapy and Radiation

Phase: N/A Priority: Normal
NCT ID: NCT00392704 Org: User:
Start: 12/31/06 End: 05/31/12 Due: 05/31/13

Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01527487 Org: User:
Start: 06/30/12 End: 07/31/16 Due: 07/31/17

Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00887575 Org: User:
Start: 06/30/09 End: 09/30/14 Due: 09/30/15

A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00789581 Org: User:
Start: 12/31/08 End: 11/30/16 Due: 11/30/17

Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients

Phase: N/A Priority: Normal
NCT ID: NCT00193323 Org: User:
Start: 08/31/01 End: 01/31/09 Due: 01/31/10